|
4,137
|
| 42676 |
Diabetes mellitus, type II
|
|
decreases_expression of
|
ARNTL
|
in pancreas, in pancreatic islet
|
|
16096055
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,462
|
| 44965 |
PPARGC1A
|
|
increases_expression of
|
ARNTL
|
|
|
17476214
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,239
|
| 58425 |
MAGED1
|
|
increases_expression of
|
ARNTL
|
|
|
20300063
|
Circadian rhythm
|
|
6,387
|
| 61627 |
ARNTL
|
|
is_part_of
|
CLOCK-BMAL1 complex
|
|
|
25955819
|
Metabolic
|
|
6,456
|
| 61412 |
ARNTL
|
|
affects_activity of
|
circadian rhythm
|
|
| 61421 |
Metformin
|
|
increases_expression of
|
ARNTL
|
via AMPK/NAMPT/SIRT1 signaling
|
|
22117616
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
6,583
|
| 63418 |
ARNTL
|
|
is_part_of
|
Core clock complex
|
|
| 63425 |
NR1D1
|
|
decreases_expression of
|
ARNTL
|
|
| 63426 |
RORA
|
|
increases_expression of
|
ARNTL
|
|
| 63474 |
ARNTL
|
|
affects_activity of
|
fat cell differentiation
|
|
| 63475 |
ARNTL
|
|
affects_activity of
|
carbohydrate metabolic process
|
in liver
|
| 63476 |
ARNTL
|
|
affects_activity of
|
gluconeogenesis
|
|
| 63477 |
ARNTL
|
|
affects_activity of
|
hepatic circadian clock
|
|
| 63478 |
ARNTL
|
|
affects_activity of
|
hypoglycemia
|
after fasting
|
| 63479 |
ARNTL
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
| 63515 |
circadian rhythm
|
|
affects_expression of
|
ARNTL
|
in pancreas
|
| 63520 |
ARNTL
|
|
decreases_activity of
|
response to oxidative stress
|
in pancreas, in pancreatic beta cells
|
| 63521 |
ARNTL
|
|
affects_expression of
|
NFE2L2
|
in pancreas, in pancreatic beta cells
|
|
25457619
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,590
|
| 63323 |
Metformin
|
|
affects_activity of
|
ARNTL
|
in liver, in muscle; via circadian rhythm
|
| 63333 |
circadian rhythm
|
|
affects_quantity of
|
ARNTL
|
in liver, in muscle
|
| 63341 |
Metformin
|
|
decreases_expression of
|
ARNTL
|
in liver
|
| 63347 |
Metformin
|
NOT |
affects_expression of
|
ARNTL
|
in muscle
|
|
22968146
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,721
|
| 64927 |
ARNTL
|
|
increases_expression of
|
NR1D1
|
|
| 64928 |
NR1D1
|
|
decreases_expression of
|
ARNTL
|
|
| 64929 |
ARNTL
|
|
affects_activity of
|
circadian rhythm
|
|
| 64940 |
RORA
|
|
increases_expression of
|
ARNTL
|
|
| 64948 |
RORB
|
|
increases_expression of
|
ARNTL
|
|
| 64950 |
RORC
|
|
increases_expression of
|
ARNTL
|
|
| 64957 |
ARNTL
|
|
affects_expression of
|
PPARA
|
|
| 64958 |
ARNTL
|
|
affects_expression of
|
DBP
|
|
| 64962 |
ARNTL
|
|
interacts (colocalizes) with
|
EP300
|
|
| 65050 |
CLOCK
|
|
increases_acetylation of
|
ARNTL
|
|
| 65058 |
SIRT1
|
|
decreases_acetylation of
|
ARNTL
|
|
| 65073 |
ARNTL
|
|
affects_activity of
|
glucose homeostasis
|
|
| 65074 |
ARNTL
|
|
affects_activity of
|
triglyceride homeostasis
|
|
| 65075 |
ARNTL
|
|
affects_activity of
|
gluconeogenesis
|
|
| 65076 |
ARNTL
|
|
affects_activity of
|
impaired glucose tolerance
|
|
| 65080 |
ARNTL
|
|
affects_expression of
|
PCK1
|
|
| 65081 |
ARNTL
|
|
affects_expression of
|
SLC2A2
|
|
| 65082 |
ARNTL
|
|
affects_activity of
|
insulin secretion
|
|
| 65095 |
ARNTL
|
|
affects_activity of
|
hepatic steatosis
|
|
| 65097 |
ARNTL
|
|
affects_activity of
|
lipid metabolic process
|
|
| 65102 |
ARNTL
|
|
affects_activity of
|
fat cell differentiation
|
|
| 65108 |
ARNTL
|
|
affects_activity of
|
increased circulating cholesterol level
|
|
|
22841001
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,747
|
| 65692 |
ARNTL
|
|
affects_quantity of
|
O2-
|
|
| 65693 |
ARNTL
|
|
affects_activity of
|
NOS3
|
|
|
27230643
|
Diabetes mellitus, type II
Insulin resistance
Cardiomyopathy, diabetic
|
|
6,858
|
| 66801 |
ARNTL
|
|
affects_activity of
|
insulin secretion
|
|
| 66803 |
ARNTL
|
|
affects_activity of
|
glucose homeostasis
|
|
|
26331226
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,861
|
| 66830 |
ARNTL
|
|
increases_activity of
|
entrainment of circadian clock
|
|
| 66838 |
CLOCK
|
|
increases_expression of
|
ARNTL
|
|
| 66839 |
RORA
|
|
increases_expression of
|
ARNTL
|
|
| 66840 |
PER-CRY complex
|
|
decreases_expression of
|
ARNTL
|
|
| 66841 |
NR1D1
|
|
decreases_expression of
|
ARNTL
|
|
| 66858 |
ARNTL
|
|
increases_expression of
|
PCK1
|
with a peak at the beginning of the active period
|
| 66901 |
Glucose
|
|
affects_expression of
|
ARNTL
|
|
| 66920 |
ARNTL
|
|
affects_activity of
|
abnormal pancreatic beta cell physiology
|
|
| 66921 |
ARNTL
|
|
affects_activity of
|
impaired glucose tolerance
|
|
| 66922 |
ARNTL
|
|
affects_activity of
|
insulin secretion
|
|
| 66923 |
ARNTL
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
| 66924 |
ARNTL
|
|
affects_activity of
|
gluconeogenesis
|
|
| 66925 |
ARNTL
|
|
affects_activity of
|
PCK1
|
in liver
|
| 66927 |
ARNTL
|
|
affects_activity of
|
leptin-mediated signaling pathway
|
|
| 67031 |
ARNTL
|
|
affects_expression of
|
mir-219
|
|
| 67049 |
mir-142-3p
|
|
decreases_quantity of
|
ARNTL
|
|
| 67050 |
mir-494
|
|
decreases_quantity of
|
ARNTL
|
|
|
26927084
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
7,314
|
| 71891 |
RAI1
|
|
increases_expression of
|
ARNTL
|
|
|
22578325
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,428
|
| 73182 |
ARNTL
|
|
increases_expression of
|
LDLR
|
in HepG2 cells; together with CLOCK protein in serum-independent manner
|
|
22913986
|
Metabolic
|
|
7,434
|
| 73198 |
ARNTL
|
|
affects_expression of
|
TGFB1
|
in embryonic fibroblasts
|
|
26458764
|
Renal
Inflammation
|
|
7,442
|
| 73218 |
ARNTL
|
|
decreases_activity of
|
cardiac hypertrophy
|
|
| 73219 |
ARNTL
|
|
decreases_activity of
|
cardiac interstitial fibrosis
|
|
| 73220 |
ARNTL
|
|
decreases_activity of
|
fibrosis
|
|
| 73221 |
ARNTL
|
|
decreases_expression of
|
COL1A1
|
|
| 73222 |
ARNTL
|
|
decreases_expression of
|
Collagen
|
|
| 73223 |
ARNTL
|
|
decreases_activity of
|
transforming growth factor beta receptor signaling pathway
|
|
| 73226 |
ARNTL
|
|
decreases_quantity of
|
Collagen I
|
|
| 73227 |
ARNTL
|
|
decreases_quantity of
|
Collagen III
|
|
| 73228 |
ARNTL
|
|
decreases_activity of
|
ECM deposition
|
|
| 73230 |
ARNTL
|
|
decreases_activity of
|
inflammatory response
|
|
|
26432841
|
Inflammation
|
|
7,467
|
| 73672 |
ARNTL
|
|
interacts (colocalizes) with
|
NPAS2
|
|
| 73673 |
ARNTL
|
|
interacts (colocalizes) with
|
CLOCK
|
|
| 73674 |
ARNTL
|
|
interacts (colocalizes) with
|
HIF1A
|
|
| 73675 |
ARNTL
|
|
interacts (colocalizes) with
|
EPAS1
|
|
|
9576906
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,521
|
| 74257 |
circadian rhythm
|
|
affects_expression of
|
ARNTL
|
in cardiomyocytes
|
| 74262 |
ARNTL
|
|
affects_activity of
|
abnormal heart electrocardiography waveform feature
|
|
| 74263 |
ARNTL
|
|
affects_activity of
|
prolonged QRS complex duration
|
|
| 74264 |
ARNTL
|
|
affects_activity of
|
prolonged RR interval
|
|
| 74265 |
ARNTL
|
|
affects_activity of
|
irregular heartbeat
|
|
| 74266 |
ARNTL
|
|
affects_activity of
|
regulation of blood pressure
|
|
| 74282 |
PPARG
|
|
interacts (colocalizes) with
|
ARNTL
|
|
| 74283 |
ARNTL
|
|
affects_activity of
|
catecholamine biosynthetic process
|
|
|
25883568
|
Cardiovascular disease
Atherosclerosis
|
|
7,526
|
| 75551 |
ARNTL
|
|
interacts (colocalizes) with
|
PER1 (E-Box, promoter)
|
|
| 75554 |
NR1D1
|
|
decreases_expression of
|
ARNTL
|
|
| 75558 |
PER-CRY complex
|
|
decreases_expression of
|
ARNTL
|
|
| 75628 |
ARNTL
|
|
interacts (colocalizes) with
|
CRY (E-Box, promoter)
|
|
| 75639 |
ARNTL
|
|
is_part_of
|
CLOCK-BMAL1 complex
|
|
| 75651 |
RORA
|
|
increases_expression of
|
ARNTL
|
|
| 75670 |
NAD/NADH ratio
|
|
affects_activity of
|
ARNTL
|
|
|
25073467
|
Gastrointestinal
Metabolic
|
|
7,593
|
| 75867 |
Obesity
|
|
affects_expression of
|
ARNTL
|
via methylation at CpG sites
|
|
23003921
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
8,247
|
| 83285 |
ARNTL
|
|
affects_activity of
|
Core clock complex
|
|
| 83294 |
ARNTL
|
|
interacts (colocalizes) with
|
CLOCK
|
|
| 83300 |
ARNTL
|
|
is_part_of
|
Core clock complex
|
|
|
21613214
|
Metabolic
|
|
8,276
|
| 83925 |
ARNTL
|
|
affects_quantity of
|
Glycerophospholipid
|
in skeletal muscle
|
| 83927 |
ARNTL
|
|
affects_quantity of
|
Sphingolipid
|
in skeletal muscle
|
|
28973848
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,555
|
| 88010 |
maternal obesity
|
|
affects_activity of
|
ARNTL
|
in pancreas
|
|
24657938
|
Diabetes mellitus, type II
Insulin resistance
Fatty pancreas disease, nonalcoholic
|
|
8,923
|
| 93264 |
ARNTL
|
|
affects_expression of
|
NR1D1
|
|
| 93297 |
ARNTL
|
|
affects_expression of
|
NR1D2
|
|
| 93303 |
ARNTL
|
|
affects_activity of
|
glucose oxidation
|
in brain and muscle
|
|
30096135
|
Metabolic
|
|
9,452
|
| 100640 |
SIRT1
|
|
decreases_acetylation of
|
ARNTL
|
|
|
22086720
|
Metabolic
|
|
9,629
|
| 101673 |
NR1D1
|
|
decreases_expression of
|
ARNTL
|
|
| 101676 |
ARNTL
|
|
is_part_of
|
Core clock complex
|
in the liver
|
|
30659595
|
Inflammation
|
|
9,630
|
| 101683 |
Triiodothyronine
|
|
decreases_expression of
|
ARNTL
|
in heart ventricles; ZT 0/24
|
|
29111822
|
Cardiovascular
|
|
10,295
|
| 106794 |
ARNTL
|
NOT |
affects_expression of
|
SLC6A4
|
in the mouse midbrain
|
|
22572884
|
Neurological
Metabolic
|
|
11,927
|
| 117295 |
ARNTL
|
|
increases_expression of
|
AGT
|
in perivascular adipose tissue
|
| 117296 |
ARNTL
|
|
increases_quantity of
|
Angiotensin II
|
in perivascular adipose tissue
|
| 117298 |
ARNTL
|
|
affects_activity of
|
regulation of blood pressure
|
|
|
29371216
|
Cardiovascular disease
|
CIDeRplus